Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
“Cocoa” Increases The Sharpness Of Vision
The acute effect of cocoa and red-berries on visual acuity and cone-mediated dark adaptation in healthy eyes. Researchers at the Universidad Complutense de Madrid have found that consuming pure cocoa can help improve vision in daylight. This recent research sheds light…
Oculus Introduces Pentacam Cornea OCT at ESCRS 2024
Oculus has unveiled the Pentacam Cornea OCT, an innovative device that integrates Scheimpflug imaging with the world’s first pericentric OCT scanning system. This dual imaging technology captures both Scheimpflug and ultra high-resolution OCT images of the cornea in just one…
Opus Genetics Receives FDA RPD Designation for OPGx-LCA5
Research Triangle Park, N.C. – August 20, 2024 – Opus Genetics has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for its ocular gene therapy, OPGx-LCA5, which aims to treat patients with…
FDA Notifies Ocugen to Begin Expanded Access Program RP
The FDA has authorized Ocugen, Inc. to launch an expanded access program (EAP) for patients aged 18 and older with retinitis pigmentosa (RP), providing early access to its promising gene therapy candidate, OCU400. The treatment has shown encouraging results in…
Bausch + Lomb’s TENEO Laser Achieves Strong LASIK Outcomes
Bausch + Lomb recently published the results of a pivotal clinical trial for its TENEO™ Excimer Laser in the Journal of Refractive Surgery. This study, which played a crucial role in securing U.S. FDA approval for the device in January…
Ocular Therapeutix Enrolls First Patient in Phase 3 Wet AMD Study
Ocular Therapeutix announced that the first patients have been enrolled in its Phase 3 SOL-R clinical trial. This study aims to assess the repeat dosing of AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) for treating wet age-related macular degeneration…
Nicox Concludes U.S. Recruitment for Phase 3 NCX 470 Trial
Nicox announced the recruitment and randomization of the final patient in the United States for its Denali Phase 3 trial of NCX 470. This milestone marks a significant step in evaluating the safety and efficacy of NCX 470 for patients…
Eyenovia and Senju Collaborate on Novel Dry Eye Treatment
Eyenovia, a leading ophthalmic company, announced a collaboration agreement with Senju Pharmaceutical to develop SJP-0035, a corneal epithelial wound healing candidate, using Eyenovia’s Optejet® dispensing technology for chronic dry eye disease treatment. Strategic Collaboration for Innovative Treatment Under the agreement,…
Trial Results for Susvimo Show Sustained Efficacy in DME and DR
Genentech and Roche released compelling 2-year data from the phase 3 Pagoda and Pavilion studies evaluating Susvimo (ranibizumab injection) 100 mg/mL, marking a significant development in the treatment landscape for diabetic macular edema (DME) and diabetic retinopathy (DR). Reintroduction of…
Okyo Pharma’s Phase 2 Trial for Neuropathic Corneal Pain
Okyo Pharma announced its plan to initiate a phase 2 clinical trial for OK-101 in the treatment of neuropathic corneal pain (NCP), scheduled to begin in the third quarter of 2024. This one-year study follows promising results from preclinical animal…